

Research Article

Rationally designed peptide-based inhibitor of A β ₄₂ fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease

 John R. Horsley^{1,*},  Blagojce Jovceviski^{2,*}, Kate L. Wegener³, Jingxian Yu¹,  Tara L. Pukala² and Andrew D. Abell¹

¹ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Department of Chemistry, School of Physical Sciences, University of Adelaide, South Australia 5005; ²Adelaide Proteomics Centre, Department of Chemistry, School of Physical Sciences, University of Adelaide, South Australia 5005; ³School of Biological Sciences, University of Adelaide, South Australia 5005

Correspondence: John R. Horsley (john.horsley@adelaide.edu.au)



Amyloid beta peptide (A β ₄₂) aggregation in the brain is thought to be responsible for the onset of Alzheimer's disease, an insidious condition without an effective treatment or cure. Hence, a strategy to prevent aggregation and subsequent toxicity is crucial. Bio-inspired peptide-based molecules are ideal candidates for the inhibition of A β ₄₂ aggregation, and are currently deemed to be a promising option for drug design. In this study, a hexapeptide containing a self-recognition component unique to A β ₄₂ was designed to mimic the β -strand hydrophobic core region of the A β peptide. The peptide is comprised exclusively of D-amino acids to enhance specificity towards A β ₄₂, in conjunction with a C-terminal disruption element to block the recruitment of A β ₄₂ monomers on to fibrils. The peptide was rationally designed to exploit the synergy between the recognition and disruption components, and incorporates features such as hydrophobicity, β -sheet propensity, and charge, that all play a critical role in the aggregation process. Fluorescence assays, native ion-mobility mass spectrometry (IM-MS) and cell viability assays were used to demonstrate that the peptide interacts with A β ₄₂ monomers and oligomers with high specificity, leading to almost complete inhibition of fibril formation, with essentially no cytotoxic effects. These data define the peptide-based inhibitor as a potentially potent anti-amyloid drug candidate for this hitherto incurable disease.

Introduction

Alzheimer's disease (AD) is the most common form of neurodegenerative disorder amongst the elderly, [1] leading to neuronal cell death and loss of cognitive function. It is the most prevalent neurodegenerative disease without a known cure, [2,3] with current drugs providing only marginal symptomatic relief. [4,5] While the exact cause of AD remains unclear, the major pathological hallmarks are neurofibrillary tangles and amyloid plaques in the brain. [6] Extracellular amyloid plaques are dense, insoluble aggregates containing the A β peptide, which in the brain are produced primarily by neurons. [7] A β is a short peptide, with the most common alloforms being either 40 or 42 residues in length, [8] and is formed via proteolysis of the amyloid precursor protein (APP) by β - and γ -secretases. [9,10] While A β ₄₀ is the more abundant amyloid peptide *in vivo*, A β ₄₂ is more neurotoxic and is responsible for peptide aggregation and fibrilization. [11] The aggregation of A β ₄₂ peptide monomers to potentially neurotoxic oligomers and fibrils is believed to be a cause of AD, [12,13] however the precise relationship between size, structure and toxicity of A β ₄₂ oligomers remains elusive. [14,15] The soluble monomeric form of A β ₄₂ has recently been found to have possible additional physiological functions, [16] so the pursuit of drugs such as secretase inhibitors may not be prudent at this point in time. Hence, the inhibition of A β aggregation seems a more appropriate

*These authors contributed equally to this work.

Received: 14 April 2020
Revised: 12 May 2020
Accepted: 18 May 2020

Accepted Manuscript online:
19 May 2020
Version of Record published:
10 June 2020

strategy.[17] The design of small molecular inhibitors to interfere with such protein-protein interactions is somewhat challenging, with the majority of those compounds currently undergoing clinical trials being non-selective and binding to A β ₄₂ with low affinity. [12] Peptide-based molecules are ideal candidates for the inhibition of A β aggregation, insofar as they can be specifically modified to increase affinity and specificity, [12] with bio-inspired peptides currently considered to be the most promising option for drug design. [18–20] A rational approach for the design of peptide-based inhibitors expressly for A β ₄₂ aggregation is to target the site where fibrilization is thought to occur, focusing on high specificity and affinity. [12] One of the sites known to be responsible for A β fibril formation is the hydrophobic core region of A β ₄₂, the self-recognition ‘nucleation site’, KLVFF (16–20 residue region). [21,22] A synthetic peptide fragment comprising this amino acid sequence is believed to bind to the corresponding region of the native peptide via hydrophobic interactions and hydrogen bonding, providing minor inhibition of A β ₄₂ aggregation. [23]

Studies have shown that A β ₄₂ oligomers and fibrils contain a β -sheet structure, with the KLVFF region crucial in this regard. [24–28] It has been suggested that a conformational change to a β -sheet geometry is the first step in the aggregation process. [29] Recently, cryogenic electron microscopy (cryo-EM) and solid-state nuclear magnetic resonance (ssNMR) have revealed a detailed characterization of A β ₄₂ monomers within the fibrils with near-atomic resolution. [30–32] These particular studies reveal that each amyloid polymorph results from the dimerization of two individual A β ₄₂ molecules, with the stacking of identical monomer pairs above and below via hydrogen bonding to form oligomers. [33] In each of these defined polymorphs, a β -strand (16–20) region is evident in both monomers, with residues exposed on the exterior surface, forming the main turn between three major β -strands. These intramolecular β -strands, together with other critical interactions, such as a salt bridge between K28 and A42, help constrain the monomer into a compact S (or LS)-shaped amyloid fold, [30,34] as depicted in Figure 1A. A slight protrusion is evident in the structure towards the end of this particular β -strand, in the vicinity of hydrophilic residues E22 and D23, where several mutations are associated with the onset of Alzheimer’s disease, [35] which may provide some insights into the origins of A β ₄₂ toxicity.




Figure 1. High-resolution cryo-EM reconstruction of A β ₄₂ fibrils, and synthesized peptides used in this study.

(A) Cryo-EM reconstruction of full-length A β ₄₂ fibrils (pdb entry: 5oqv) [32] shows that residues 16–20 (red) are central to a parallel β -sheet region, identified on the exterior surface of the fibrils in several A β ₄₂ polymorphs. Residue F20 has been shown to occupy two distinct orientations on the fibril surface (fibril axis indicated by dashed line). (B) Structures of control peptides wAib and KLVFF. The rationally designed β -strand peptides **1** (L-isomer) and **2** (D-isomer) were assessed to determine their ability to prevent A β ₄₂ fibril formation. (C) Design strategy of peptide inhibitors (peptide **2** in this instance) consisting of the recognition sequence (blue) which targets residues 16–20 (red) of A β ₄₂, and the wAib β -breaker moiety (orange) to prevent fibril formation.

Hence, these three-dimensional structures provide an excellent foundation for the rational design of inhibitors that can bind to a specific, accessible location on the monomer/fibril surface to prevent A β ₄₂ aggregation.

Numerous derivatives of KLVFF have been developed to improve inhibitory effects, [36–42] with only pentapeptides or longer showing significant binding to the amyloid peptide. [43] A previous study based on the KLVFF motif, found that peptides containing D-amino acids were more active inhibitors of A β than their L-counterparts. [44] The D-amino acid peptide fragment, klvff, has a modest inhibitory effect on A β ₄₂ aggregation, albeit superior to that of the L-enantiomer, KLVFF. [45] The use of D-amino acids offers advantages of increased metabolic stability and resistance to proteases, [46] decreased immunogenicity, [47] as well as an enhanced ability to cross the blood brain barrier (BBB). [48,49] Murphy and Kiessling were among the first to report incorporation of a ‘disruption element’ into peptides containing the KLVFF recognition element, which was shown to alter A β aggregation pathways. [50] Specifically, the recognition element facilitates the binding of the peptide-based inhibitor to the growing A β fibril or its precursor, while the disruption element is designed to hinder further propagation and reduce toxicity. [51,52] Peptides containing various ‘ β -strand breakers’ acting as a disruption element have been shown to inhibit A β aggregation. [11,12] Proline residues were first used in this context, and exhibited a moderate inhibitory effect against A β ₄₂ when located in the centre of the peptide sequence in order to prevent the formation of a β -sheet structure. [53] The achiral, geminally disubstituted aminobutyric acid (Aib) residue has also found moderate success when used in this manner, [2,54,55] and possesses a much stronger β -strand breaking potential than proline. [56] The placement of a β -strand breaker residue in the centre of short peptide inhibitors based on the KLVFF recognition element is known to distort the β -strand conformation, [57] and is thus not structurally homologous to the A β oligomer/fibril binding site. [52] The Gazit group designed a novel oligomerization inhibitor comprising a dipeptide, with D-tryptophan (D-Trp) coupled to a C-terminal Aib β -breakage moiety. [56] They found that tryptophan demonstrated the highest amyloidogenic propensity of any amino acid, [2] with the indole moiety thought to interact with the aromatic rings of the phenylalanine residues located in the central hydrophobic core region of the amyloid peptide via π - π stacking, thus competing with A β monomers for interaction with the growing fibrils. [56] While the peptide exhibited good binding affinity for A β monomers, [58] it was designed to be non-specific in sequence, and has the capacity to inhibit the toxic aggregation of other amyloid peptides, including IAPP, α -synuclein, and calcitonin. [59] Studies have shown that peptides with a high affinity for A β are better inhibitors of A β fibrilization, [60] but peptide-based inhibitors designed expressly for A β ₄₂ aggregation also require high specificity. Hence, retention of the β -strand geometry of the peptide-based inhibitor for binding specificity is crucial, as is judicious placement of the disruption domain. Although a KLVFF fragment has been shown to inhibit A β ₄₂ aggregation to a small degree, [23] it has a tendency to self-aggregate, which is not a desirable property for an effective inhibitor [61].

With the aforementioned in mind, we present a specific A β ₄₂ inhibitor (see peptide 2 in Figure 1) based on the KLVFF recognition site of A β ₄₂ (residues 16–20), that does not self-aggregate. The peptide comprises all D-amino acids, coupled to a C-terminal Aib ‘ β -breakage’ moiety, to exploit the synergy between the recognition and disruption components. The peptide was rationally designed to incorporate features such as hydrophobicity, β -sheet propensity, and charge, in order to increase affinity and specificity, and provide a robust interconnection with A β ₄₂, as all three elements play a critical role in the aggregation process. [46,62] Herein, we present structural studies of the peptide-based inhibitor and describe its effect on A β ₄₂ aggregation and toxicity.

Materials and methods

Peptide synthesis

Peptides 1 and 2 were synthesized using Solid Phase Peptide Synthesis (SPPS). Fmoc-based SPPS and commercially available reagents were used for the synthesis of both peptides. 2-Chlorotrityl resin preloaded with Fmoc-Aib-OH (0.80 mmol g⁻¹, 1.0 g, 1 equiv) was used for both peptides. The unreacted active sites on the resin were capped with DCM/MeOH/DIPEA (17:2:1, 2 \times 25 ml) for 30 min and the resin washed with DCM (x3), DMF (x3) and DCM (x3). *N*-Fmoc deprotection was conducted by treating the resin with 25% piperidine/DMF (25 ml) for 30 min before washing with DCM (x3), DMF (x3) and DCM (x3). Each sequential amino acid was coupled using the following molar ratios of reagents: Fmoc-amino acids were each dissolved in DMF (20 ml), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU)/DMF (0.5 M, 2 equiv) and DIPEA (4 equiv). The resin was then washed with DCM (x3) and

DMF (x3) followed by DCM (x3), and the coupling procedures repeated. The coupling time was a minimum of 2 h in all cases. Fmoc-(D)-Trp-OH was next added to each peptide. Thereafter, Fmoc-(L)-Phe-OH, Fmoc-(L)-Val-OH, Fmoc-(L)-Leu-OH, and Fmoc-(L)-Lys(Boc)-OH were sequentially added to peptide **1**, whereas all D-amino acids, Fmoc-(D)-Phe-OH, Fmoc-(D)-Val-OH, Fmoc-(D)-Leu-OH, and Fmoc-(D)-Lys(Boc)-OH were used to synthesize peptide **2**. Following coupling with the final residue for each peptide, treatment with 1.5% TFA/DCM (15 ml) for 10 min resulted in cleavage from the resin. Peptides **1** and **2** were each dissolved in TFA/DCM (50% v/v) for 30 min to remove the Boc protecting group. Each peptide was placed under vacuum before being purified using reverse phase HPLC. KLVFF and wAib-OH (controls) were also synthesized using SPPS, and purified using reverse phase HPLC. Notably, a number of techniques including ¹H NMR, were used to confirm that peptides **1** and **2** have been stable for more than two years.

¹H NMR data for peptides

Peptide **1** ¹H NMR (600 MHz, DMSO-d₆) δ 10.79 (s, 1H, OH), 8.47 (d, 1H, NH Leu, *J* = 8.0 Hz), 8.30 (d, 1H, NH Trp, *J* = 8.4 Hz), 8.13–8.10 (m, 3H, NH Aib, NH₂ terminal Lys), 7.93 (d, 1H, NH Val, *J* = 9.0 Hz), 7.87 (d, 1H, NH Phe, *J* = 7.7 Hz), 7.75 (br s, 1H, NH indole), 7.66 (d, 1H, ArH, *J* = 7.9 Hz), 7.30 (d, 1H, ArH, *J* = 8.1 Hz), 7.12 (d, 1H, ArH, *J* = 2.1 Hz), 7.10–7.04 (m, 4H, ArH), 6.98 (t, 1H, ArH, *J* = 7.5 Hz), 6.94 (d, 2H, ArH, *J* = 7.1 Hz), 4.54–4.49 (m, 2H, CαH Phe, CαH Trp), 4.40 (m, 1H, CαH Leu), 4.08 (m, 1H, CαH Val), 3.76 (m, 1H, CαH Lys), 3.12 (m, 1H, CαH (Trp) CHH), 2.84 (m, 1H, CαH (Trp) CHH), 2.70 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 2.65 (m, 1H, CαH (Phe) CHH), 2.51 (m, 1H, CαH (Phe) CHH), 1.88 (m, 1H, CαH (Val) CH), 1.68–1.62 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 1.58 (m, 1H, CαH (Leu) CH₂CH), 1.51–1.46 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 1.40–1.34 (m, 2H, CαH (Leu) CH₂CH), 1.37 (s, 3H, Aib CH₃), 1.32 (s, 3H, Aib CH₃), 1.30–1.27 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 0.87–0.82 (m, 6H, (Leu) 2 × CH₃), 0.75–0.73 (m, 6H, (Val) 2 × CH₃).

HRMS [M + H]⁺ calc'd = 777.4663, [M + H]⁺ found = 777.4674 (Supplementary Figure S11).

Peptide **2** ¹H NMR (600 MHz, DMSO-d₆) δ 10.80 (s, 1H, OH), 8.47 (d, 1H, NH Leu, *J* = 8.0 Hz), 8.07 (s, 1H, NH Aib), 8.05 (d, 1H, NH Trp, *J* = 8.2 Hz), 7.99 (d, 1H, NH Val, *J* = 9.1 Hz), 7.95 (d, 1H, NH Phe, *J* = 8.1 Hz), 7.73 (br s, 1H, NH indole), 7.57 (d, 1H, ArH, *J* = 7.9 Hz), 7.31 (d, 1H, ArH, *J* = 8.1 Hz), 7.21–7.12 (m, 6H, ArH), 7.05 (t, 1H, ArH, *J* = 7.1 Hz), 6.96 (d, 1H, ArH, *J* = 7.0 Hz), 4.57–4.52 (m, 2H, CαH Phe, CαH Trp), 4.40 (m, 1H, CαH Leu), 4.11 (m, 1H, CαH Val), 3.76 (t, 1H, CαH Lys, *J* = 6.2 Hz), 3.07 (m, 1H, CαH (Trp) CHH), 2.98–2.92 (m, 2H, CαH (Trp) CHH, CαH (Phe) CHH), 2.75 (m, 1H, CαH (Phe) CHH), 2.70 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 1.88 (m, 1H, CαH (Val) CH), 1.69–1.63 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 1.59 (m, 1H, CαH (Leu) CH₂CH), 1.52–1.46 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 1.42 (m, 1H, CαH (Leu) CHHCH), 1.35 (m, 1H, CαH (Leu) CHHCH), 1.32 (s, 3H, Aib CH₃), 1.31–1.23 (m, 2H, CαH (Lys) CH₂CH₂CH₂CH₂), 1.27 (s, 3H, Aib CH₃), 0.88–0.83 (m, 6H, (Leu) 2 × CH₃), 0.74–0.72 (m, 6H, (Val) 2 × CH₃).

HRMS [M + H]⁺ calc'd = 777.4663, [M + H]⁺ found = 777.4706 (Supplementary Figure S12).

IR spectroscopy

Infrared spectra of peptides **1** and **2** (dried samples) were collected on a PerkinElmer Spectrum 100 FT-IR spectrometer, with attenuated total reflectance (ATR) imaging capabilities, fitted with a ZnSe crystal, with an average reading taken from four scans at 4 cm⁻¹ resolution.

High-performance liquid chromatography

The synthetic peptides were analyzed and purified by reverse phase HPLC, using a Gilson GX-271 preparative system equipped with Trilution LC 2.1 software, with a Supelco C18 column (250 × 10 mm) at a flow rate of 4 ml min⁻¹. ACN/TFA (100/0.0008 by v/v) and water/TFA (100/0.001 by v/v) solutions were used as organic and aqueous buffers, respectively.

High resolution mass spectroscopy

High resolution mass spectral data were analyzed using an Ultimate 3000 RSL HPLC (Thermo Fisher Scientific Inc., MA) and an LTQ Orbitrap XL ETD using a flow injection method, with a flow rate of 5 μl/min. The HPLC flow is interfaced with the mass spectrometer using the Electrospray source (Thermo Fisher Scientific Inc., MA). Mass spectra were obtained over a range of 100 < m/z < 1000. Data was analyzed using XCalibur software (Version 2.0.7, Thermo Fisher Scientific).

Molecular modelling

The lowest-energy conformers for the peptides were determined in the gas phase by the NWChem 6.6 package [63] with tight convergence criteria using a hybrid B3LYP functional with 6–31G** basis set for all atoms. Conformational analysis, including dihedral angles, overall molecular lengths and intramolecular hydrogen bond lengths, were conducted using the Chimera 1.11 software. [64]

A β ₄₂ aggregation assays

Monomerization of A β ₄₂ (Adelab Scientific) was prepared by NaOH treatment as described previously [65] whereas mature A β ₄₂ fibrils were prepared at 37°C for 24 h with shaking (50 rpm). The ability of various inhibitors to prevent A β ₄₂ fibril formation was assessed using an *in situ* thioflavin-T (ThT) (20 μ M) assay. Non-monomerized A β ₄₂ (100 μ M) was examined across a range of molar ratios (1 : 1, 1 : 2, 1 : 10 and 1 : 20) (A β ₄₂:inhibitor) in the absence and presence of inhibitors. Assays were performed in PBS (pH 7.4) and 1% DMSO at 35°C in quiescence. The ability of the inhibitors to prevent A β ₄₂ fibrilization was determined by comparing the ThT fluorescence at the conclusion of each assay. [66] The inhibition of primary-nucleation mediated A β ₄₂ aggregation was also monitored using an *in situ* ThT assay where monomerized A β ₄₂ (10 μ M) was incubated in the absence and presence of inhibitors under conditions stated above at 25°C. All assays were performed using a FLUOstar Optima plate reader (BMG Lab Technologies) with excitation and emission wavelengths set at 440 nm and 490 nm, respectively. All assays were performed at least three times and data are reported as mean \pm SEM of three independent assays.

Seeded α -synuclein (α S) aggregation assays

Plasmid (pT7–7, Addgene) encoding for wild-type (WT) human α S (SNCA, UniProt accession number: P37840) were kindly donated by Prof. Heath Ecroyd (University of Wollongong, Australia). Expression and purification of monomeric α S WT was performed as described previously. [67] Following purification, monomeric α S (50 μ M in PBS) was heated and stirred at 45°C for 24 h prior to sonication. The ability of peptides 1 and 2 to prevent α S fibril formation was assessed using an α S elongation assay. [67] This assay measures the ability of the designed inhibitors to inhibit the elongation of α S fibrils using short pre-formed α S seed fibrils. Elongation of α S fibrils was monitored using an *in situ* ThT (20 μ M) assay. Inhibitors were added at 1 : 1, 2 : 1 and 1 : 2 molar ratios (α S:inhibitor) to monomeric α S (50 μ M) in PBS (pH 7.4) with 5% (w/w) α S seed fibrils. All assays were performed at least three times and data are reported as mean \pm SEM of these independent assays.

TEM

The presence and morphology of A β ₄₂ fibrils were imaged by TEM where 2 μ l aliquots from the end-point of ThT aggregation assays were adsorbed on to carbon-coated electron microscopy grids (SPI Supplies) and negatively stained with 2% (w/v) uranyl acetate. [68] Images were viewed using a Philips CM100 transmission electron microscope at 45 000 \times magnification.

Nile red assays

Nile red fluorescence was used to determine the relative amount of exposed hydrophobicity of A β ₄₂ fibrils and measured using a Cary Eclipse fluorescence spectrophotometer (Varian). Fibrils (10 μ M in PBS, pH 7.4) in the presence and absence of inhibitors were labelled with Nile red (10 μ M). Labelled samples were incubated for 5 min at room temperature prior to fluorescence measurement. The excitation wavelength was set at 595 nm and emission wavelength was recorded from 500–800 nm. The slit widths for excitation and emission spectra were both set at 5 nm.

Cell culture and cell viability assays

Mouse neuroblastoma Neuro-2a cells were kindly donated by Dr. David Bersten (University of Adelaide, Australia) and grown in DMEM/F12 media containing 10% fetal calf serum at 37°C in 5% CO₂/95% air atmosphere. Cells were seeded at 3×10^4 cells/well in aforementioned media and equilibrated for 24 h prior to addition of pre-formed A β ₄₂ fibrils (50 μ M) in the absence and presence of each inhibitor at a 1 : 2 (A β ₄₂ : inhibitor) molar ratio. Cells were then incubated for 48 h at 37°C in 5% CO₂/95% air atmosphere prior to cell viability measurement. The ability of the inhibitors to prevent cytotoxicity induced by the addition of

exogenous A β_{42} fibrils was assessed using a thiazolyl blue tetrazolium bromide (MTT) assay. Media was removed post-incubation and replaced with serum-free media containing MTT (0.25 mg/ml) and incubated for 2 h at 37°C in 5% CO₂/95% air atmosphere. Media containing MTT was removed and cells were lysed with DMSO prior to absorbance measurement at 570 nm using a FLUOstar Optima plate reader (BMG Lab Technologies). Statistical analysis was performed using Prism 8.0 (GraphPad).

Native ion mobility—mass spectrometry (IM-MS)

IM-MS was performed as described previously [68] on a Synapt G1 HDMS (Waters) with a nanoelectrospray source. A β_{42} (10 μ M) was incubated in the absence and presence of peptide 1/2 at a 1 : 10 molar ratio (A β_{42} : peptide 1/2) in 200 mM ammonium acetate (pH 6.8) and loaded onto platinum-coated borosilicate glass capillaries prepared in-house (Harvard Apparatus). To minimize gas-phase structural rearrangement the following instrument parameters were applied: capillary voltage, 1.65 kV; sample cone voltage, 20 V; source temperature, 25°C; trap collision energy, 10–20 V (5 V increments); transfer collision energy, 10 V; trap gas: 4.5 l/h; backing pressure, 4.0 mbar. IM cell instrument parameters: wave velocity: 300 m/s; transfer t-wave height: 6 V; transfer wave velocity: 250 m/s. Mass spectra and ATD data were analyzed using MassLynx (v4.1) and Driftscope (v2.7) respectively (Waters).

Results and discussion

Peptide design

Peptide 2 and its natural analogue 1 (Figure 1B) were designed specifically to inhibit the aggregation of A β_{42} . The peptide sequence is based on the hydrophobic core, KLVFF recognition region of A β_{42} , with the terminal phenylalanine residue of each replaced with D-Trp which is known to enhance amyloidogenicity, and with an appended C-terminal achiral Aib residue to act as a β -strand breaker. The peptides were designed to adopt a β -strand geometry and bind specifically to the KLVFF region of A β_{42} by virtue of their sequence homology, with the Aib residue proposed to interfere with the aggregation process.

As previously demonstrated, [27] a peptide-based inhibitor containing a preorganized β -strand conformation, facilitates binding to early β -structured oligomers to a greater extent than unstructured monomers bind oligomers. With respect to oligomeric amyloid structures, it has been proposed that a parallel β -sheet forms between neighboring A β_{42} monomers at the central 15–21 residue region. [40] An antiparallel β -sheet has also been suggested for the interaction between short inhibitory peptides containing D-amino acids and the all L-A β_{42} , generating energetically favourable hydrogen bonding. [52] The C-terminal Aib residue is intended to sterically block hydrogen bonding between the β -sheets in either orientation, while also increasing the overall hydrophobicity of the peptide. An Aib moiety is known to promote helicity which then disrupts β -sheet formation, leading to inhibition of amyloid formation. [55] The mass of the peptide was restricted to 776 Da, without compromising functionality, since compounds with a mass in excess of 1000 Da are largely excluded from passing through the BBB. [69] Peptide fragments, KLVFF and D-Trp-Aib-OH (hereafter referred to as wAib, Figure 1B) were used as controls for the aggregation studies, as peptides 1 and 2 were both derived from the KLVFF region of A β_{42} , and each contain an Aib residue coupled to a D-Trp at their C-termini.

Conformational analysis of peptides

The backbones of peptides 1 and 2 were shown to adopt a β -strand geometry by ¹H NMR, IR and molecular modelling. Specifically, C α H (*i*) to NH (*i* + 1) and C β H₂ (*i*) to NH (*i* + 1) ROESY interactions for residues 1–5 were observed (excluding Aib, see Supplementary Figures S1, S2). Four ³J_{NHCOH} coupling constants between 7.7 Hz and 9.0 Hz were observed for peptide 1, while ³J_{NHCOH} coupling constants between 8.0 Hz and 9.1 Hz were observed for residues 2–5 in peptide 2 (excluding Aib), in accordance with a β -strand conformation. [70] The IR spectrum of peptide 1 shows a strong Amide I band at 1637 cm⁻¹, characteristic of a β -strand conformation, together with an Amide II band at 1550 cm⁻¹ (N-H bending vibrations, parallel β -sheet), [71] and Amide A band at 3275 cm⁻¹ (N-H stretching, Supplementary Figure S3). The IR spectrum for peptide 2 is also characteristic of a β -strand conformation, with a strong Amide I band at 1631 cm⁻¹, and an Amide II band at 1525 cm⁻¹, indicative of an antiparallel β -sheet (Supplementary Figure S4). [71] The lowest energy conformer for the D-peptide 2 was determined by density functional theory (DFT) calculations to further define the backbone geometry (see Materials and Methods section for details). The backbone dihedral angles for 2 indicate a β -strand geometry throughout the peptide, from D-Lys (1) to D-Trp (5), with the exception of the Aib residue

(Supplementary Table S1). This result supports the IR and ^1H NMR spectroscopic data, which also confirms an extended β -strand conformation, with the exception of the C-terminal Aib ‘ β -breaker’ moiety. Furthermore, critical distances calculated for $\text{C}\alpha\text{H}$ (i) to NH ($i+1$) and $\text{C}\beta\text{H}_2$ (i) to NH ($i+1$) are in accordance with a β -strand conformation (Supplementary Figures S5–S7 and Supplementary Table S2). [72]

Peptide 2 significantly inhibits $\text{A}\beta_{42}$ fibril elongation

Peptides **1** and **2** were each tested for inhibition of $\text{A}\beta_{42}$ elongation, with control peptides KLVFF and wAib used for comparison. The ability of the peptides to inhibit $\text{A}\beta_{42}$ aggregation was assessed using an *in vitro* thioflavin-T (ThT) fluorescence assay (see Materials and Methods section for details), which exhibits increased fluorescence with the extent of cross β -sheet structure, characteristic of amyloid fibril formation. [38] In the absence of inhibitors, $\text{A}\beta_{42}$ follows aggregation kinetics whereby fibril elongation begins immediately (i.e. seeding-like kinetics), reaching a plateau at ~ 6 h (Figure 2A) likely due to the high concentration of $\text{A}\beta_{42}$ (100 μM) as observed previously [73]. In the presence of wAib, no drastic change in ThT fluorescence was observed over time, until a 20-fold excess led to an observable decrease in fluorescence (Figure 2A; dark grey). In the presence of KLVFF, small decreases in fluorescence were observed at 2-fold and 10-fold excess compared with $\text{A}\beta_{42}$ alone (Figure 2A; light grey). Conversely, in the presence of either peptides **1** or **2**, a dramatic decrease in fluorescence was observed compared with $\text{A}\beta_{42}$ alone (Figure 2A; dark and light blue, respectively). Essentially, peptide **2** achieved near complete inhibition at a 1 : 2 molar ratio (Figure 2A,B).

The specificity of each peptide to $\text{A}\beta_{42}$ was also assessed by performing an α -synuclein (αS) fibril elongation assay and measuring the change in ThT fluorescence. An abnormal accumulation of α -synuclein protein in the brain is associated with the onset of Parkinson’s disease. [74] In the presence of these inhibitors, only peptide **1** displayed a distinct decrease in fluorescence at a 1 : 2 molar ratio (αS :inhibitor) (Supplementary Figure S10). Notably, peptide **2** showed no effect on α -synuclein aggregation, demonstrating the significance of the specific D-amino acid sequence, and the secondary structure within this potent peptide-based inhibitor for specificity towards $\text{A}\beta_{42}$.

Transmission electron microscopy (TEM) was also used to examine the morphology of $\text{A}\beta_{42}$ fibrils in the absence and presence of the inhibitory peptides at the conclusion of the aggregation assays. In the absence of inhibitors, $\text{A}\beta_{42}$ incubated alone is observed to form a dense network typical of amyloid fibrils (Figure 2C). In the presence of either wAib or KLVFF, $\text{A}\beta_{42}$ also exhibits a dense fibrillar structure at the molar ratio tested (1 : 2) ($\text{A}\beta_{42}$:inhibitor) (Figure 2C). Previous studies, using a KLVFF-NH₂ peptide as a control, observed similar dense fibrilization when incubated with $\text{A}\beta_{42}$ at a similar stoichiometric ratio. [37,42] In the presence of peptide **1**, the abundance of $\text{A}\beta_{42}$ fibrils is reduced considerably when compared with the two controls (Figure 2C). However, in the presence of peptide **2**, small fibril seeds are sparsely distributed, with no large fibrillar structures observed (Figure 2C), highlighting its capacity as a potent inhibitor. Overall, the data from the ThT assays are commensurate with the associated TEM images for both controls and peptide inhibitors.

Due to the absence of an observable lag-phase where primary nucleation would occur, changes in ThT fluorescence during the elongation phase (Figure 1A, 0.5–2.5 h) were examined to determine the elongation rate from the range of molar ratios tested (Figure 3A and Supplementary Table S3). Both wAib and KLVFF do not drastically affect the rate of $\text{A}\beta_{42}$ fibril elongation (Figure 3A and Supplementary Table S3). In contrast, peptides **1** and **2** significantly reduce the rate of fibril elongation such that a 10-fold excess of peptide **2** remarkably halts fibril elongation altogether (Figure 3A and Supplementary Table S3). In addition, the relationship between inhibitor concentration and $\text{A}\beta_{42}$ was determined to provide evidence as to whether peptides **1** and **2** interact with $\text{A}\beta_{42}$ species to attenuate fibril formation (Figure 3B). As the concentration of wAib and KLVFF increases there is little effect on fibril elongation (i.e. less than a 50% decrease in the elongation rate at a 20-fold excess). However, as the concentration of peptides **1** and **2** increases there is a dramatic reduction in fibril elongation, suggesting that these peptides interact with fibrillar $\text{A}\beta_{42}$ and prevent further monomer recruitment.

In addition, the mechanism(s) in which peptides **1** and **2** prevent $\text{A}\beta_{42}$ fibrilization were probed by examining their ability to disassemble pre-formed fibrils (Figure 3C). Fibril elongation was allowed to proceed for 4.5 h, at which point a 10-fold molar excess of either peptide **1** or **2** was added (Figure 3C, red dashed line). In contrast with peptide **1**, peptide **2** exhibits a plateau in ThT fluorescence for the duration of the assay (Figure 3C). Collectively, this indicates that the peptides, particularly **2**, do not disassemble pre-formed fibrils but interact with the ends of fibrils to prevent subsequent elongation. Overall the data indicates that both peptides, in particular peptide **2**, preferentially interact with $\text{A}\beta_{42}$ fibrils to prevent further fibrilization. The fact




Figure 2. Peptide 2 as a most effective inhibitor of Aβ₄₂ fibril elongation.

(A) ThT fluorescence assay monitoring fibril elongation and formation of Aβ₄₂ in the absence (100 μM, black) and presence of wAib (dark grey), KLVFF (light grey) and peptide inhibitors **1** (blue) and **2** (purple) at various molar ratios (ranging from 1 : 1 to 1 : 20 Aβ₄₂ : inhibitor). (B) The degree of inhibition of Aβ₄₂ fibril elongation (calculated at the conclusion of the assay) of wAib, KLVFF, **1** and **2** across the range of molar ratios. Data reported in A and B is presented as mean ± SEM (*n* = 3). (C) TEM images of mature Aβ₄₂ fibrils in the absence and presence of inhibitors at a 1 : 2 molar ratio (Aβ₄₂ : inhibitor). Scale bars represent 200 nm.




Figure 3. Peptide 2 drastically reduces the rate of Aβ₄₂ fibril elongation.

(A) The change in ThT fluorescence during the elongation phase of Aβ₄₂ (100 μM) fibril formation in the absence (black) and presence (grey, blue and purple) of inhibitors at a range of molar ratios (0–2.5 h from Figure 2A). (B) The rate of Aβ₄₂ fibril elongation as a function of inhibitor concentration (mM) was fitted with a non-linear one-phase decay fit. (C) ThT fluorescence assay of Aβ₄₂ (10 μM) spiked after 4.5 h (red dashed line) with peptides 1 and 2 (100 μM) during incubation where no decrease in fibrilization was observed. Data reported is presented as mean ± SEM (*n* = 3).

that peptide 2 does not disassemble existing fibrils, thereby potentially avoiding the formation of toxic oligomers, reinforces the feasibility of the proposed binding mode (mechanism) where a robust interconnection is made between the two by virtue of their sequence homology, heterochiral nature, and complementary β-strand conformation.

Peptide 2 also interacts with Aβ₄₂ monomers by inhibiting primary nucleation mediated Aβ₄₂ fibril formation

The ability of peptides 1 and 2 to prevent primary nucleation mediated Aβ₄₂ fibril formation was also assessed by ThT fluorescence assays. Under conditions that induce primary nucleation fibril formation (typically 5–10 μM) [65,75] and in the absence of inhibitors, Aβ₄₂ follows sigmoidal-like aggregation kinetics at the concentration examined (10 μM) whereby the lag-phase and subsequent fibril elongation begins at ~1.5 h, reaching a plateau at ~13 h (Figure 4A). In the presence of peptide 1, no distinct change in aggregation kinetics was observed at a 1:1 molar ratio (Aβ₄₂:inhibitor) compared with Aβ₄₂ alone (Figure 4A, blue), conferring only 2% inhibition (Figure 4B). At 1:10 and 1:20 molar ratios, a significant decrease in total fibril formation was observed, with plateaus at 10 h and 4 h, respectively with no change in lag-phase (i.e. primary nucleation) or elongation rate (Figure 4A). Subsequently, peptide 1 conferred 3% (1:1), 41% (1:10) and 70% (1:20)




Figure 4. Peptide 2 as a most effective inhibitor of Aβ₄₂ fibrilization.

(A) ThT fluorescence assay monitoring fibril formation of Aβ₄₂ in the absence (10 μM, black) and presence of peptide inhibitors 1 (blue) and 2 (purple) at various molar ratios (ranging from 1 : 1 to 1 : 20, Aβ₄₂ : inhibitor). (B) The degree of inhibition of Aβ₄₂ fibril formation (calculated at the conclusion of the assay) induced by peptides 1 and 2 across the range of molar ratios examined. Data reported in A and B is presented as mean ± SEM (*n* = 3).

inhibition, whilst peptide 2 afforded 36% (1 : 1) and 60% (1 : 10) inhibition (Figure 4A,B). At a 1 : 20 molar ratio, peptide 2 drastically changes the aggregation kinetics of Aβ₄₂, extending the lag-phase to 7 h and slowing the rate of fibril elongation (Figure 4A, purple), resulting in 79% inhibition (Figure 4B). We propose that peptide 2 can interact with Aβ₄₂ monomers in order to prevent fibril formation, however further studies are needed to substantiate this notion, and these will be discussed in the following section. When combined with our fibril elongation assay data, the mechanism(s) of inhibition utilized by 1 and 2 are distinct as both predominantly interact with Aβ₄₂ fibrils, whilst peptide 2 also interacts with Aβ₄₂ monomers by inhibiting primary nucleation and subsequent fibril elongation.

Peptide 2 induces conformational changes on aggregation-prone Aβ₄₂ monomers

Native ion-mobility mass spectrometry (IM-MS) and molecular modelling were used to determine whether peptides 1 and 2 modulate the conformation of aggregation-prone Aβ₄₂ monomers as an additional means of fibril inhibition (Figure 5). Native MS is a useful biophysical tool to probe the tertiary and quaternary structures, and dynamics of non-covalent protein-peptide assemblies (Figure 5A). When coupled to ion-mobility separation, the conformation of aggregation-prone assemblies can be visualized and assessed by observing the arrival time distribution (ATD) of individual protein species (e.g. monomers and dimers) during fibril formation (Figure 5B,C). In the absence of peptides 1 and 2, Aβ₄₂ monomers undergo a disorder to order transition during incubation, as evidenced by the decrease in ATD (2.82 ms to 1.96 ms) after 2 h incubation, which is typical of fibril forming proteins [68] (Figure 5B,C). Upon addition of either peptides 1 or 2 prior to incubation, an ATD shift was observed. In the presence of peptide 1 (1.65 ms) and 2 (1.89 ms) this distribution (and hence monomer conformation) did not change further during aggregation (Figure 5B,C), which demonstrates that Aβ₄₂ monomers adopt a compact (i.e. more ordered) conformation upon immediate addition of inhibitor. The degree of heterogeneity within the monomer can be reported by the full-width half maximum (FWHM) (Figure 5D), where high FWHM values indicate monomers adopting more conformations across a broader ATD, and lower FWHM values indicate monomers adopting a comparatively restricted ensemble of conformations. The conformational heterogeneity of Aβ₄₂ monomers during incubation is reduced (1.88 to 1.34 ms) (Figure 5B,C). The immediate addition and incubation of 1 did not induce any change in conformational




Figure 5. Probing the interaction between peptides 1 and 2, and $A\beta_{42}$ monomers by native IM-MS and molecular modelling.

(A) Native IM-MS of $A\beta_{42}$ (10 μ M) in 200 mM ammonium acetate (pH 7.0) at 0 h with the monomer⁴⁺ (M^{4+} ; m/z 1128) being selected for ATD analysis (green box). (B and C) ATDs of $A\beta_{42}$ M^{4+} during incubation with peptide 1 (B) and 2 (C) at a 1 : 10 molar ratio ($A\beta_{42}$: peptide 1/2) at low activation energies (10–20 V). $A\beta_{42}$ monomers in the absence of peptide 1 or 2 exhibit a disorder to order transition (black to grey) after 2 h incubation (37°C). The addition of peptides 1 (dark blue, 0 h; light blue, 2 h) or 2 (dark orange, 0 h; light orange, 2 h) immediately induces a conformational change of $A\beta_{42}$ monomers and persists during the initial stages of fibril formation (left panels). (D) FWHM time for $A\beta_{42}$ M^{4+} ATDs in the absence and presence of 1 and 2 after 0 h and 2 h incubation (mean \pm SD, $n = 3$). (E) Molecular modelling illustrates the interaction between a truncated segment of $A\beta_{42}$ (residues 14–22) and peptide 2 (light blue), mediated by strong H-bonding between residues klvfw of 2, and KLVFF of $A\beta_{42}$, by virtue of their sequence homology (H-bond distances in Å, dashed lines).

heterogeneity of $A\beta_{42}$ monomers during incubation (1.26 to 1.30 ms) (Figure 5B, inset). However, upon immediate addition and subsequent incubation of $A\beta_{42}$ with 2, we observed an increase in conformational heterogeneity (1.19 to 1.41 ms) (Figure 5D). This compaction and change in conformational heterogeneity of $A\beta_{42}$ monomers induces similar structural changes that are normally required for fibrilization, yet are unable to anneal on fibrils (i.e. fibril elongation), as has been previously suggested. [30]

In light of this ATD data, molecular modelling was employed to further probe the interaction between $A\beta_{42}$ monomers and peptide 2. The modelling data demonstrates that peptide 2 is capable of forming six strong intermolecular H-bonds with a truncated segment of $A\beta_{42}$ (residues 14–22; HQKLVFFAE) (Figure 5E). The data also indicates that, like KLVFF, peptide 1 is prone to self-association via intermolecular H-bonding (Supplementary Figure S8A). Thus, there is competition with KLVFF and peptide 1, between self-aggregation and interaction with $A\beta_{42}$. In contrast, peptide 2 does not self-aggregate (Supplementary Figure S8B) and preferentially binds to $A\beta_{42}$. We propose that peptide 2 induces conformational changes to $A\beta_{42}$ monomers through transient interactions, which is analogous to various fibrilization inhibitors such as molecular chaperones [76] and flavones. [77] The data shows that peptide 2 is capable of forming a strong H-bond network

specific to residues 16–20 of A β ₄₂. This ‘in-register’ parallel β -sheet architecture is found in the hydrophobic central core region of A β [78] and is common to most other pathological human amyloids. [79] This arrangement, with the all D-peptide forming intermolecular hydrogen bonds with the all L-A β ₄₂ peptide, positions the side chains of the adjacent peptides opposite to one another, which would help alleviate charge repulsion between lysine residues. Supplementary Figure S9 shows the model of peptide 2 from above, with residues 1–5 comprising a β -strand structure, with the exception of the Aib residue. Each backbone carbonyl and amide hydrogen of amino acids 1–5 are positioned as a β -strand, whereas those associated with the Aib residue adopt a different orientation, which is not conducive to intermolecular hydrogen bonding to A β ₄₂ from above or below. We have previously shown the geminally disubstituted Aib residue to reduce backbone flexibility within a peptide. [80] Collectively, our results demonstrate that peptide 2 interacts with both monomeric and fibrillar A β ₄₂ to inhibit fibril formation and elongation. This interaction is sequence-specific, with the C-terminal Aib β -breakage moiety of 2 preventing further intermolecular hydrogen bonding, thus impeding the self-assembly process.

Peptide 2 significantly reduces hydrophobicity of A β ₄₂ fibrils

To further understand the mechanism(s) by which 1 and 2 interact with A β ₄₂, we investigated whether these peptides could reduce the exposed hydrophobicity of A β ₄₂ fibrils (Figure 6A,B). Fibrils were labelled with Nile red (10 μ M) in the absence and presence of peptides 1 and 2 at the molar ratios tested in the ThT fluorescence assays (see Materials and Methods section for details). No shift in the emission wavelength was observed in the absence or presence of peptides 1 and 2 (Figure 6A,B). Upon treatment with either peptide, there was an observable concentration-dependent decrease in Nile red fluorescence, with peptide 2 inducing a considerably greater decrease in fluorescence intensity compared with peptide 1 at a 1 : 20 molar ratio (A β ₄₂ : inhibitor) (Figure 6A,B). This indicates that peptide 2 decreases the surface hydrophobicity of A β ₄₂ fibrils, potentially reducing their toxicity.

Peptide 2 significantly reduces cytotoxicity of A β ₄₂ fibrils

The cytotoxic effects of A β ₄₂ aggregation on various cell types are well known, [81] and here we investigate the ability of these peptide-based inhibitors to decrease cytotoxicity in the presence of A β ₄₂ fibrils using an MTT cell viability assay (see Materials and Methods section for details). Firstly, the presence of inhibitors to specifically exert cytotoxic effects on cells was examined (Figure 7). Cells treated with both A β ₄₂ and inhibitors were analyzed at a 1 : 2 molar ratio (A β ₄₂ : inhibitor). Across all compounds tested, there was no drastic change in cell viability in the absence of A β ₄₂, indicating that the inhibitors (and controls) alone do not affect cell viability. Upon addition of exogenous A β ₄₂ fibrils to murine neuroblastoma Neuro-2a cells, a substantial decrease in cell viability was observed (~56% decrease, Figure 7A,B). The addition of either wAib or KLVFF in the presence of A β ₄₂ fibrils does not significantly increase cell viability compared with cells incubated with A β ₄₂ alone (Figure 7A). However, the addition of peptides 1 and 2 significantly increases cell viability to ~90% and ~99%, respectively, compared with A β ₄₂ alone (Figure 7A). Overall, the data indicates that peptides 1 and 2 are both biocompatible, and reduce A β ₄₂ fibril-induced toxicity at the cellular level. Most notably, peptide 2 incubated with A β ₄₂, drastically restores cell viability.




Figure 6. Peptide 2 significantly reduces hydrophobicity of A β ₄₂ fibrils.

(A and B) Nile red emission fluorescence of A β ₄₂ fibrils (10 μ M) in the absence and presence of peptides 1 (A) and 2 (B) at various molar ratios (1 : 1 to 20 : 1, peptide : A β ₄₂).




Figure 7. Peptide 2 significantly restores cell viability upon addition of Aβ₄₂ fibrils.

(A and B) Neuro-2a cells were treated with various inhibitors in the presence (A) and absence (B) of pre-formed Aβ₄₂ fibrils (50 μM). Cells treated with both Aβ₄₂ and inhibitors were examined at a 1 : 2 molar ratio (Aβ₄₂ : inhibitor). Cells were incubated for 24 h and cell viability was measured upon addition of MTT (0.5 mg/ml). Data reported is presented as mean ± SEM (*n* = 3) (** *P* < 0.01, **** *P* < 0.0001).

In summary, the aggregation of Aβ₄₂ monomers to potentially neurotoxic oligomers and fibrils is believed to be responsible for the onset of AD, with the first step in this process being a conformational change to a β-sheet geometry. Inhibitors designed expressly for Aβ₄₂ aggregation require high specificity, hence the design and synthesis of peptide 2 was based on the β-strand-containing KLVFF region of the amyloid peptide, together with an Aib β-sheet disruption element. This is the first study of its type to successfully exploit the synergy between a recognition and disruption component incorporated into a peptide comprising D-amino acids, for the specific inhibition of Aβ₄₂ aggregation. NMR and IR data, together with molecular modelling, confirm the presence of a β-strand conformation throughout the inhibitor, with the exception of the Aib ‘β-breaker’ moiety. Experimental data show that peptide 2 prevents fibril formation, specifically towards Aβ₄₂, and significantly reduces the rate of fibril elongation, such that a two-fold excess essentially halts fibril elongation altogether. This peptide-based inhibitor preferentially interacts with Aβ₄₂ fibrils by slowing elongation, likely interacting with the ends of fibrils, to prevent further fibril formation. Aggregation assays, native IM-MS and molecular modelling were used to demonstrate that peptide 2 is also capable of interacting with Aβ₄₂ monomers to prevent oligomerization and inhibit aggregation. These results shed light on the binding mechanism and further underline the significance of the β-strand structure, and particular D-amino acid sequence, for specificity towards Aβ₄₂. Cell viability assays demonstrate that when incubated with Aβ₄₂ in a 2:1 molar ratio, peptide 2 exhibits essentially no cytotoxic effect whatsoever. Moreover, an effective inhibitor should not self-aggregate and, unlike the KLVFF peptide fragment, 2 fulfils this requirement. Collectively, our results show peptide 2 to be a potent inhibitor of Aβ₄₂ monomers, oligomers and fibrils, and thus offers considerable promise for further development as a drug candidate in the treatment of AD. We set out to exploit the synergy between the recognition and disruption components incorporated into the peptide-based inhibitor, and found that the sum is greater than its parts. The synergistic rationale employed in this study could potentially be applied to enhance therapeutic efficacy for fibril forming proteins that are associated with other neurodegenerative diseases.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

The authors acknowledge the Australian Research Council (ARC) Discovery Project (DP180101581) and the Centre of Excellence for Nanoscale BioPhotonics (CNBP) for financial support. We also acknowledge funding from the Australian Research Council (ARC) Discovery Project (DP170102033) and National Health and Medical Research Council (NHMRC) (44113151).

Open Access

Open access for this article was enabled by the participation of University of Adelaide in an all-inclusive *Read & Publish* pilot with Portland Press and the Biochemical Society under a transformative agreement with CAUL.

Author Contributions

J.R.H. designed the research, synthesized the peptides, and prepared the manuscript. B.J. designed the research, conducted assays and prepared the manuscript. K.L.W. conducted assays. J.Y. undertook computational studies. T.L.P. and A.D.A. contributed to the manuscript.

Acknowledgements

We thank the Australian National Fabrication Facility (ANFF) for providing the analytical facilities used in this work, and Flinders Analytical (Flinders University, Australia) for access and support to IM-MS instrumentation. We also thank Dr. Lisa O'Donovan and Adelaide Microscopy (both University of Adelaide) for TEM technical assistance, and Prof. John A. Carver (Australian National University) for his input. Computational aspects of this work were supported by an award under the National Computational Merit Allocation Scheme for JY on the National Computing Infrastructure (NCI) National Facility at the Australian National University.

Abbreviations

AD, Alzheimer's disease; ATD, arrival time distribution; BBB, blood brain barrier; FWHM, full-width half maximum; IM-MS, ion-mobility mass spectrometry; SPPS, solid phase peptide synthesis; TEM, transmission electron microscopy; WT, wild type.

References

- van Groen, T., Schemmert, S., Brenner, O., Gremer, L., Ziehm, T., Tusche, M. et al. (2017) The A β oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. *Sci. Rep.* **7**, 16275 <https://doi.org/10.1038/s41598-017-16565-1>
- Frydman-Marom, A., Convertino, M., Pellarin, R., Lampel, A., Shaltiel-Karyo, R., Segal, D. et al. (2011) Structural basis for inhibiting β -amyloid oligomerization by a non-coded β -breaker-substituted endomorphin analogue. *ACS Chem. Biol.* **6**, 1265–1276 <https://doi.org/10.1021/cb200103h>
- Warner, C.J.A., Dutta, S., Foley, A.R. and Raskatov, J.A. (2016) Introduction of d-glutamate at a critical residue of A β 42 stabilizes a prefibrillary aggregate with enhanced toxicity. *Chemistry* **22**, 11967–11970 <https://doi.org/10.1002/chem.201601763>
- Cacabelos, R. (2018) Have there been improvements in Alzheimer's disease drug discovery over the past 5 years? *Expert Opin. Drug Discov.* **13**, 523–538 <https://doi.org/10.1080/17460441.2018.1457645>
- Nie, Q., Du, X.G. and Geng, M.Y. (2011) Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. *Acta Pharmacol. Sin.* **32**, 545 <https://doi.org/10.1038/aps.2011.14>
- Kasim, J.K., Kavianinia, I., Harris, P.W.R. and Brimble, M.A. (2019) Three decades of amyloid beta synthesis: challenges and advances. *Front Chem* **7**, 472 <https://doi.org/10.3389/fchem.2019.00472>
- Yan, R. and Vassar, R. (2014) Targeting the β secretase BACE1 for Alzheimer's disease therapy. *Lancet Neurol.* **13**, 319–329 [https://doi.org/10.1016/S1474-4422\(13\)70276-X](https://doi.org/10.1016/S1474-4422(13)70276-X)
- Barrera Guisasola, E.E., Andujar, S.A., Hubin, E., Broersen, K., Kraan, I.M., Méndez, L. et al. (2015) New mimetic peptides inhibitors of A β aggregation. Molecular guidance for rational drug design. *Eur. J. Med. Chem.* **95**, 136–152 <https://doi.org/10.1016/j.ejmech.2015.03.042>
- Lin, Y.-S., Bowman, G.R., Beauchamp, K.A. and Pande, V.S. (2012) Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer. *Biophys. J.* **102**, 315–324 <https://doi.org/10.1016/j.bpj.2011.12.002>
- Lee, H.J., Korshavn, K.J., Nam, Y., Kang, J., Paul, T.J., Kerr, R.A. et al. (2017) Structural and mechanistic insights into development of chemical tools to control individual and inter-related pathological features in Alzheimer's disease. *Chemistry* **23**, 2706–2715 <https://doi.org/10.1002/chem.201605401>
- Kaffy, J., Brinet, D., Soulier, J.-L., Correia, I., Tonalì, N., Fera, K.F. et al. (2016) Designed glycopeptidomimetics disrupt protein–protein interactions mediating amyloid β -peptide aggregation and restore neuroblastoma cell viability. *J. Med. Chem.* **59**, 2025–2040 <https://doi.org/10.1021/acs.jmedchem.5b01629>
- Goyal, D., Shuaib, S., Mann, S. and Goyal, B. (2017) Rationally designed peptides and peptidomimetics as inhibitors of amyloid- β (A β) aggregation: potential therapeutics of Alzheimer's disease. *ACS Comb. Sci.* **19**, 55–80 <https://doi.org/10.1021/acscmbosci.6b00116>
- Coimbra, J.R.M., Marques, D.F.F., Baptista, S.J., Pereira, C.M.F., Moreira, P.I., Dinis, T.C.P. et al. (2018) Highlights in BACE1 inhibitors for Alzheimer's disease treatment. *Front. Chem.* **6**, 178 <https://doi.org/10.3389/fchem.2018.00178>
- Bisceglia, F., Natalello, A., Serafini, M.M., Colombo, R., Verga, L., Lanni, C. et al. (2018) An integrated strategy to correlate aggregation state, structure and toxicity of AB 1–42 oligomers. *Talanta* **188**, 17–26 <https://doi.org/10.1016/j.talanta.2018.05.062>
- Oliveri, V., Zimbone, S., Giuffrida, M.L., Bellia, F., Tomasello, M.F. and Vecchio, G. (2018) Porphyrin cyclodextrin conjugates modulate amyloid beta peptide aggregation and cytotoxicity. *Chemistry* **24**, 6349–6353 <https://doi.org/10.1002/chem.201800807>
- Parsons, C.G. and Rammes, G. (2017) Preclinical to phase II amyloid beta (A β) peptide modulators under investigation for Alzheimer's disease. *Expert Opin. Invest. Drugs* **26**, 579–592 <https://doi.org/10.1080/13543784.2017.1313832>
- Oren, O., Banerjee, V., Taube, R. and Papo, N. (2018) An A β 42 variant that inhibits intra- and extracellular amyloid aggregation and enhances cell viability. *Biochem. J.* **475**, 3087–3103 <https://doi.org/10.1042/BCJ20180247>
- Cardoso, M.H., Cândido, E.S., Oshiro, K.G.N., Rezende, S.B. and Franco, O.L. (2018) Peptides containing d-amino acids and retro-inverso peptides: General applications and special focus on antimicrobial peptides. In *Peptide Applications in Biomedicine, Biotechnology and Bioengineering* (Koutsopoulos, S., ed.), pp. 131–155, Woodhead Publishing

- 19 Siddiqi, M.K., Alam, P., Iqbal, T., Majid, N., Malik, S., Nusrat, S. et al. (2018) Elucidating the inhibitory potential of designed peptides against amyloid fibrillation and amyloid associated cytotoxicity. *Front. Chem.* **6**, 311 <https://doi.org/10.3389/fchem.2018.00311>
- 20 Yeoh, Y.Q., Yu, J., Polyak, S.W., Horsley, J.R. and Abell, A.D. (2018) Photopharmacological control of cyclic antimicrobial peptides. *ChemBioChem* **19**, 2591–2597 <https://doi.org/10.1002/cbic.201800618>
- 21 Lowe, T.L., Strzelec, A., Kiessling, L.L. and Murphy, R.M. (2001) Structure–function relationships for inhibitors of β -amyloid toxicity containing the recognition sequence KLVFF. *Biochemistry* **40**, 7882–7889 <https://doi.org/10.1021/bi002734u>
- 22 Tjernberg, L.O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A.R., Thyberg, J. et al. (1996) Arrest of beta-Amyloid fibril formation by a pentapeptide ligand. *J. Biol. Chem.* **271**, 8545–8548 <https://doi.org/10.1074/jbc.271.15.8545>
- 23 Arai, T., Sasaki, D., Araya, T., Sato, T., Sohma, Y. and Kanai, M. (2014) A cyclic KLVFF-Derived peptide aggregation inhibitor induces the formation of less-toxic off-pathway amyloid- β oligomers. *ChemBioChem* **15**, 2577–2583 <https://doi.org/10.1002/cbic.201402430>
- 24 Tran, L. and Ha-Duong, T. (2015) Exploring the Alzheimer amyloid- β peptide conformational ensemble: A review of molecular dynamics approaches. *Peptides* **69**, 86–91 <https://doi.org/10.1016/j.peptides.2015.04.009>
- 25 Breydo, L., Kurouski, D., Rasool, S., Milton, S., Wu, J.W., Uversky, V.N. et al. (2016) Structural differences between amyloid beta oligomers. *Biochem. Biophys. Res. Commun.* **477**, 700–705 <https://doi.org/10.1016/j.bbrc.2016.06.122>
- 26 Matsubara, T., Yasumori, H., Ito, K., Shimoaka, T., Hasegawa, T. and Sato, T. (2018) Amyloid- β fibrils assembled on ganglioside-enriched membranes contain both parallel β -sheets and turns. *J. Biol. Chem.* **293**, 14146–14154 <https://doi.org/10.1074/jbc.RA118.002787>
- 27 Cheng, P.-N., Liu, C., Zhao, M., Eisenberg, D. and Nowick, J.S. (2012) Amyloid β -sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. *Nat. Chem.* **4**, 927 <https://doi.org/10.1038/nchem.1433>
- 28 Tjernberg, L.O., Lilliehöök, C., Callaway, D.J.E., Näslund, J., Hahne, S., Thyberg, J. et al. (1997) Controlling amyloid β -peptide fibril formation with protease-stable ligands. *J. Biol. Chem.* **272**, 12601–12605 <https://doi.org/10.1074/jbc.272.19.12601>
- 29 Zhang-Haagen, B., Biehl, R., Nagel-Steger, L., Radulescu, A., Richter, D. and Willbold, D. (2016) Monomeric amyloid beta peptide in hexafluoroisopropanol detected by small angle neutron scattering. *PLoS ONE* **11**, e0150267 <https://doi.org/10.1371/journal.pone.0150267>
- 30 Colvin, M.T., Silvers, R., Ni, Q.Z., Can, T.V., Sergeyev, I., Rosay, M. et al. (2016) Atomic resolution structure of monomeric A β 42 amyloid fibrils. *J. Am. Chem. Soc.* **138**, 9663–9674 <https://doi.org/10.1021/jacs.6b05129>
- 31 Wälti, M.A., Ravotti, F., Arai, H., Glabe, C.G., Wall, J.S., Böckmann, A. et al. (2016) Atomic-resolution structure of a disease-relevant A β (1–42) amyloid fibril. *Proc. Natl Acad. Sci. U.S.A.* **113**, E4976–E4984 <https://doi.org/10.1073/pnas.1600749113>
- 32 Gremer, L., Schölzel, D., Schenk, C., Reinartz, E., Labahn, J., Ravelli, R.B.G. et al. (2017) Fibril structure of amyloid- β (1–42) by cryo-electron microscopy. *Science* **358**, 116–119 <https://doi.org/10.1126/science.aao2825>
- 33 Eisenberg, D.S. and Sawaya, M.R. (2017) Structural studies of amyloid proteins at the molecular level. *Annu. Rev. Biochem.* **86**, 69–95 <https://doi.org/10.1146/annurev-biochem-061516-045104>
- 34 Xiao, Y., Ma, B., McElheny, D., Parthasarathy, S., Long, F., Hoshi, M. et al. (2015) A β (1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. *Nat. Struct. Mol. Biol.* **22**, 499 <https://doi.org/10.1038/nsmb.2991>
- 35 Eisenberg, D.S. and Sawaya, M.R. (2016) Implications for Alzheimer's disease of an atomic resolution structure of amyloid- β (1–42) fibrils. *Proc. Natl Acad. Sci. U.S.A.* **113**, 9398–9400 <https://doi.org/10.1073/pnas.1610806113>
- 36 Chafekar, S.M., Malda, H., Merx, M., Meijer, E.W., Viertel, D., Lashuel, H.A. et al. (2007) Branched KLVFF tetramers strongly potentiate inhibition of β -amyloid aggregation. *ChemBioChem* **8**, 1857–1864 <https://doi.org/10.1002/cbic.200700338>
- 37 Austen, B.M., Paleologou, K.E., Ali, S.A.E., Qureshi, M.M., Allsop, D. and El-Agnaf, O.M.A. (2008) Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's β -amyloid peptide. *Biochemistry* **47**, 1984–1992 <https://doi.org/10.1021/bi701415b>
- 38 Kino, R., Araya, T., Arai, T., Sohma, Y. and Kanai, M. (2015) Covalent modifier-type aggregation inhibitor of amyloid- β based on a cyclo-KLVFF motif. *Bioorg. Med. Chem. Lett.* **25**, 2972–2975 <https://doi.org/10.1016/j.bmcl.2015.05.027>
- 39 Gordon, D.J., Sciarretta, K.L. and Meredith, S.C. (2001) Inhibition of β -amyloid(40) fibrillogenesis and disassembly of β -amyloid(40) fibrils by short β -amyloid congeners containing N-methyl amino acids at alternate residues. *Biochemistry* **40**, 8237–8245 <https://doi.org/10.1021/bi002416v>
- 40 Matharu, B., El-Agnaf, O., Razvi, A. and Austen, B.M. (2010) Development of retro-inverso peptides as anti-aggregation drugs for β -amyloid in Alzheimer's disease. *Peptides* **31**, 1866–1872 <https://doi.org/10.1016/j.peptides.2010.06.033>
- 41 Kokkoni, N., Stott, K., Amijee, H., Mason, J.M. and Doig, A.J. (2006) N-Methylated peptide inhibitors of β -amyloid aggregation and toxicity. optimization of the inhibitor structure. *Biochemistry* **45**, 9906–9918 <https://doi.org/10.1021/bi060837s>
- 42 Rajasekhar, K., Suresh, S.N., Manjithaya, R. and Govindaraju, T. (2015) Rationally designed peptidomimetic modulators of A β toxicity in Alzheimer's disease. *Sci. Rep.* **5**, 8139 <https://doi.org/10.1038/srep08139>
- 43 Hamley, I.W. (2007) Peptide fibrillization. *Angew. Chem. Int. Ed. Engl.* **46**, 8128–8147 <https://doi.org/10.1002/anie.200700861>
- 44 Chalifour, R.J., McLaughlin, R.W., Lavoie, L., Morissette, C., Tremblay, N., Boulé, M. et al. (2003) Stereoselective interactions of peptide inhibitors with the β -amyloid peptide. *J. Biol. Chem.* **278**, 34874–34881 <https://doi.org/10.1074/jbc.M212694200>
- 45 Arai, T., Araya, T., Sasaki, D., Taniguchi, A., Sato, T., Sohma, Y. et al. (2014) Rational design and identification of a non-peptidic aggregation inhibitor of amyloid- β based on a pharmacophore motif obtained from cyclo[-Lys-Leu-Val-Phe-Phe-]. *Angew. Chem. Int. Ed. Engl.* **53**, 8236–8239 <https://doi.org/10.1002/anie.201405109>
- 46 Jagota, S. and Rajadas, J. (2013) Synthesis of d-amino acid peptides and their effect on beta-amyloid aggregation and toxicity in transgenic caenorhabditis elegans. *Med. Chem. Res.* **22**, 3991–4000 <https://doi.org/10.1007/s00044-012-0386-2>
- 47 Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E. et al. (2016) Selection and characterization of tau binding D-Enantiomeric peptides with potential for therapy of Alzheimer disease. *PLoS ONE* **11**, e0167432 <https://doi.org/10.1371/journal.pone.0167432>
- 48 Leithold, L.H.E., Jiang, N., Post, J., Ziehm, T., Schartmann, E., Kutzsche, J. et al. (2016) Pharmacokinetic properties of a novel d-peptide developed to be therapeutically active against toxic β -amyloid oligomers. *Pharm. Res.* **33**, 328–336 <https://doi.org/10.1007/s11095-015-1791-2>
- 49 Spanopoulou, A., Heidrich, L., Chen, H.-R., Frost, C., Hrle, D., Malideli, E. et al. (2018) Designed macrocyclic peptides as nanomolar amyloid inhibitors based on minimal recognition elements. *Angew. Chem. Int. Ed. Engl.* **57**, 14503–14508 <https://doi.org/10.1002/anie.201802979>
- 50 Ghanta, J., Shen, C.-L., Kiessling, L.L. and Murphy, R.M. (1996) A strategy for designing inhibitors of β -amyloid toxicity. *J. Biol. Chem.* **271**, 29525–29528 <https://doi.org/10.1074/jbc.271.47.29525>

- 51 Etienne, M.A., Aucoin, J.P., Fu, Y., McCarley, R.L. and Hammer, R.P. (2006) Stoichiometric inhibition of amyloid β -protein aggregation with peptides containing alternating α,α -disubstituted amino acids. *J. Am. Chem. Soc.* **128**, 3522–3523 <https://doi.org/10.1021/ja0600678>
- 52 Sciarretta, K.L., Gordon, D.J. and Meredith, S.C. (2006) Peptide-based inhibitors of amyloid assembly. *Methods Enzymol.* **413**, 273–312 [https://doi.org/10.1016/S0076-6879\(06\)13015-3](https://doi.org/10.1016/S0076-6879(06)13015-3)
- 53 Soto, C., Kindy, M.S., Baumann, M. and Frangione, B. (1996) Inhibition of Alzheimer's amyloidosis by peptides that prevent β -Sheet conformation. *Biochem. Biophys. Res. Commun.* **226**, 672–680 <https://doi.org/10.1006/bbrc.1996.1413>
- 54 Botz, A., Gasparik, V., Devillers, E., Hoffmann, A.R.F., Caillon, L., Chelain, E. et al. (2015) (R)- α -trifluoromethylalanine containing short peptide in the inhibition of amyloid peptide fibrillation. *Peptide Sci.* **104**, 601–610 <https://doi.org/10.1002/bip.22670>
- 55 Gilead, S. and Gazit, E. (2004) Inhibition of amyloid fibril formation by peptide analogues modified with α -aminoisobutyric acid. *Angew. Chem. Int. Ed. Engl.* **116**, 4133–4136 <https://doi.org/10.1002/ange.200353565>
- 56 Frydman-Marom, A., Rechter, M., Shefler, I., Bram, Y., Shalev, D.E. and Gazit, E. (2009) Cognitive-Performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. *Angew. Chem. Int. Ed. Engl.* **121**, 2015–2020 <https://doi.org/10.1002/ange.200802123>
- 57 Formaggio, F., Bettio, A., Moretto, V., Crisma, M., Toniolo, C. and Broxterman, Q.B. (2003) Disruption of the β -sheet structure of a protected pentapeptide, related to the β -amyloid sequence 17–21, induced by a single, heliogenic C α -tetrasubstituted α -amino acid. *J. Pept. Sci.* **9**, 461–466 <https://doi.org/10.1002/psc.503>
- 58 Parsons, C.G., Ruitenbergh, M., Freitag, C.E., Sroka-Saidi, K., Russ, H. and Rammes, G. (2015) MRZ-99030 – A novel modulator of A β aggregation: I – mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). *Neuropharmacology* **92**, 158–169 <https://doi.org/10.1016/j.neuropharm.2014.12.038>
- 59 Frydman-Marom, A., Shaltiel-Karyo, R., Moshe, S. and Gazit, E. (2011) The generic amyloid formation inhibition effect of a designed small aromatic β -breaking peptide. *Amyloid* **18**, 119–127 <https://doi.org/10.3109/13506129.2011.582902>
- 60 Bett, C.K., Serem, W.K., Fontenot, K.R., Hammer, R.P. and Garno, J.C. (2010) Effects of peptides derived from terminal modifications of the A β central hydrophobic core on A β fibrillization. *ACS Chem. Neurosci.* **1**, 661–678 <https://doi.org/10.1021/cn900019r>
- 61 Zhang, L., Yagnik, G., Peng, Y., Wang, J., Xu, H.H., Hao, Y. et al. (2013) Kinetic studies of inhibition of the amyloid beta (1–42) aggregation using a ferrocene-tagged β -sheet breaker peptide. *Anal. Biochem.* **434**, 292–299 <https://doi.org/10.1016/j.ab.2012.11.025>
- 62 Barz, B. and Strodel, B. (2016) Understanding amyloid- β oligomerization at the molecular level: the role of the fibril surface. *Chemistry* **22**, 8768–8772 <https://doi.org/10.1002/chem.201601701>
- 63 Valiev, M., Bylaska, E.J., Govind, N., Kowalski, K., Straatsma, T.P., van Dam, H.J.J. et al. (2010) NWChem: a comprehensive and scalable open-source solution for large scale molecular simulations. *Comput. Phys. Commun.* **181**, 1477 <https://doi.org/10.1016/j.cpc.2010.04.018>
- 64 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. et al. (2004) UCSF chimera—A visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612 <https://doi.org/10.1002/jcc.20084>
- 65 Ryan, T.M., Caine, J., Mertens, H.D.T., Kirby, N., Nigro, J., Breheny, K. et al. (2013) Ammonium hydroxide treatment of A β produces an aggregate free solution suitable for biophysical and cell culture characterization. *PeerJ* **1**, e73–e73 <https://doi.org/10.7717/peerj.73>
- 66 Ecroyd, H. and Carver, J.A. (2008) The effect of small molecules in modulating the chaperone activity of α B-crystallin against ordered and disordered protein aggregation. *FEBS J.* **275**, 935–947 <https://doi.org/10.1111/j.1742-4658.2008.06257.x>
- 67 Buell, A.K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T.P.J. et al. (2014) Solution conditions determine the relative importance of nucleation and growth processes in α -synuclein aggregation. *Proc. Natl Acad. Sci. U.S.A.* **111**, 7671–7676 <https://doi.org/10.1073/pnas.1315346111>
- 68 Liu, Y., Jovcevski, B. and Pukala, T.L. (2019) C-Phycocyanin from spirulina inhibits α -synuclein and amyloid- β fibril formation but not amorphous aggregation. *J. Nat. Prod.* **82**, 66–73 <https://doi.org/10.1021/acs.jnatprod.8b00610>
- 69 Jiang, N., Frenzel, D., Scharfmann, E., van Groen, T., Kadish, I., Shah, N.J. et al. (2016) Blood-brain barrier penetration of an A β -targeted, arginine-rich, d-enantiomeric peptide. *Biochim. Biophys. Acta* **1858**, 2717–2724 <https://doi.org/10.1016/j.bbamem.2016.07.002>
- 70 Fernando, S.R.L., Kozlov, G.V. and Ogawa, M.Y. (1998) Distance dependence of electron transfer along artificial beta-strands at 298 and 77K. *Inorg. Chem.* **37**, 1900–1905 <https://doi.org/10.1021/ic970369y>
- 71 Zhuang, W., Hayashi, T. and Mukamel, S. (2009) Coherent multidimensional vibrational spectroscopy of biomolecules: Concepts, simulations, and challenges. *Angew. Chem. Int. Ed. Engl.* **48**, 3750–3781 <https://doi.org/10.1002/anie.200802644>
- 72 Gillespie, P., Cicariello, J. and Olson, G.L. (1997) Conformational analysis of dipeptide mimetics. *Pept. Sci.* **43**, 191–217 [https://doi.org/10.1002/\(SICI\)1097-0282\(1997\)43:3<191::AID-BIP2>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1097-0282(1997)43:3<191::AID-BIP2>3.0.CO;2-Q)
- 73 Hasegawa, K., Yamaguchi, I., Omata, S., Gejyo, F. and Naiki, H. (1999) Interaction between A β (1–42) and A β (1–40) in Alzheimer's β -Amyloid fibril formation in vitro. *Biochemistry* **38**, 15514–15521 <https://doi.org/10.1021/bi991161m>
- 74 Li, B., Ge, P., Murray, K.A., Sheth, P., Zhang, M., Nair, G. et al. (2018) Cryo-EM of full-length α -synuclein reveals fibril polymorphs with a common structural kernel. *Nat. Commun.* **9**, 3609 <https://doi.org/10.1038/s41467-018-05971-2>
- 75 Cater, J.H., Kumita, J.R., Zeineddine Abdallah, R., Zhao, G., Bernardo-Gancedo, A., Henry, A. et al. (2019) Human pregnancy zone protein stabilizes misfolded proteins including preeclampsia- and Alzheimer's-associated amyloid beta peptide. *Proc. Natl Acad. Sci. U.S.A.* **116**, 6101 <https://doi.org/10.1073/pnas.1817298116>
- 76 Cox, D., Selig, E., Griffin, M.D.W., Carver, J.A. and Ecroyd, H. (2016) Small heat-shock proteins prevent α -synuclein aggregation via transient interactions and their efficacy is affected by the rate of aggregation. *J. Biol. Chem.* **291**, 22618–22629 <https://doi.org/10.1074/jbc.M116.739250>
- 77 Das, S., Pukala, T.L. and Smid, S.D. (2018) Exploring the structural diversity in inhibitors of α -synuclein amyloidogenic folding, aggregation, and neurotoxicity. *Front. Chem.* **6**, 181 <https://doi.org/10.3389/fchem.2018.00181>
- 78 Benzinger, T.L.S., Gregory, D.M., Burkoth, T.S., Miller-Auer, H., Lynn, D.G., Botto, R.E. et al. (1998) Propagating structure of Alzheimer's β -amyloid (10–35) is parallel β -sheet with residues in exact register. *Proc. Natl Acad. Sci. U.S.A.* **95**, 13407–13412 <https://doi.org/10.1073/pnas.95.23.13407>
- 79 Gorkovskiy, A., Thurber, K.R., Tycko, R. and Wickner, R.B. (2014) Locating folds of the in-register parallel β -sheet of the Sup35p prion domain infectious amyloid. *Proc. Natl Acad. Sci. U.S.A.* **111**, E4615–E4622 <https://doi.org/10.1073/pnas.1417974111>
- 80 Yu, J., Horsley, J.R., Moore, K.E., Shapter, J.G. and Abell, A.D. (2014) The effect of a macrocyclic constraint on electron transfer in helical peptides: A step towards tunable molecular wires. *Chem. Commun.* **50**, 1652 <https://doi.org/10.1039/c3cc47885h>
- 81 Ziehm, T., Brenner, O., van Groen, T., Kadish, I., Frenzel, D., Tuschke, M. et al. (2016) Increase of positive Net charge and conformational rigidity enhances the efficacy of d-enantiomeric peptides designed to eliminate cytotoxic A β species. *ACS Chem. Neurosci.* **7**, 1088–1096 <https://doi.org/10.1021/acschemneuro.6b00047>